collection
MENU ▼
Read by QxMD icon Read
search

Rheumatoid Arthritis

shared collection
226 papers 25 to 100 followers
https://www.readbyqxmd.com/read/29037899/the-management-of-first-line-biologic-therapy-failures-in-rheumatoid-arthritis-current-practice-and-future-perspectives
#1
REVIEW
Ennio Giulio Favalli, Maria Gabriella Raimondo, Andrea Becciolini, Chiara Crotti, Martina Biggioggero, Roberto Caporali
The introduction of biologic disease-modifying anti-rheumatic drugs (bDMARDs) has dramatically changed the management of rheumatoid arthritis (RA). However, in a real-life setting about 30-40% of bDMARD treated patients experience drug discontinuation because of either inefficacy or adverse events. According to international recommendations, to date the best strategy for managing first-line bDMARD failures has not been defined yet and available data (especially on TNF inhibitors [TNFis]) seem to drive toward a personalized approach for the individual patient...
October 14, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28980088/rituximab-in-clinical-practice-dosage-drug-adherence-ig-levels-infections-and-drug-antibodies
#2
Jon Thorkell Einarsson, Max Evert, Pierre Geborek, Tore Saxne, Maria Lundgren, Meliha C Kapetanovic
The objective of this study is to explore the following: (1) the impact of two different initial doses and cumulative 2-year dose of rituximab (RTX) on drug adherence and predictors of adherence to treatment in rheumatoid arthritis (RA) patients in an observational clinical setting, (2) immunoglobulin levels (IgG/IgM/IgA) during repeated treatment and their relation to infections, and (3) development of anti-rituximab antibodies (ADA). All RA patients receiving RTX from January 2003 to April 2012 at the department were included...
October 4, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29089055/assessing-risk-of-liver-enzyme-elevation-in-patients-with-immune-mediated-diseases-and-different-hepatitis-b-virus-serostatus-receiving-anti-tnf-agents-a-nested-case-control-study
#3
Ying-Ming Chiu, Mei-Shu Lai, K Arnold Chan
BACKGROUND: Liver enzyme elevation is an important and common adverse effect among patients with immune-mediated diseases who receive tumour necrosis factor inhibitors (anti-TNF), and has various causes. Hence, we evaluated the relative risks of developing liver enzyme elevation in anti-TNF users with differing hepatitis B virus (HBV) infection status. METHODS: At a hospital in central Taiwan, 407 patients with rheumatoid arthritis, ankylosing spondylitis, or psoriasis/psoriatic arthritis received anti-TNF therapy between 1 January 2004 and 30 June 2012...
November 1, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28970215/metabolic-and-cardiovascular-benefits-of-hydroxychloroquine-in-patients-with-rheumatoid-arthritis-a-systematic-review-and-meta-analysis
#4
Claire Rempenault, Bernard Combe, Thomas Barnetche, Cécile Gaujoux-Viala, Cédric Lukas, Jacques Morel, Charlotte Hua
OBJECTIVE: Cardiovascular disease (CVD) is the leading cause of mortality in patients with rheumatoid arthritis (RA). Hydroxychloroquine (HCQ) has been shown to improve survival rates in other inflammatory diseases. We aimed to assess the available literature on the cardiovascular impact of HCQ in patients with RA. METHODS: We systematically searched for studies evaluating the effects of HCQ on cardiovascular outcomes of known risk factors for CVD in patients with RA...
September 25, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29042750/current-perspective-on-rituximab-in-rheumatic-diseases
#5
REVIEW
Tommaso Schioppo, Francesca Ingegnoli
The steadily increasing knowledge regarding pathogenetic mechanisms in autoimmune rheumatic diseases has paved the way to different therapeutic approaches. In particular, the market entry of biologics has dramatically modified the natural history of rheumatic chronic inflammatory diseases with a meaningful impact on patients' quality of life. Among the wide spectrum of available biological treatments, rituximab (RTX), first used in the treatment of non-Hodgkin's lymphoma, was later approved for rheumatoid arthritis and anti-neutrophil cytoplasmic antibodies-associated vasculitis...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28916714/interleukin-6-blockade-raises-ldl-via-reduced-catabolism-rather-than-via-increased-synthesis-a-cytokine-specific-mechanism-for-cholesterol-changes-in-rheumatoid-arthritis
#6
Jamie Robertson, Duncan Porter, Naveed Sattar, Chris J Packard, Muriel Caslake, Iain McInnes, David McCarey
OBJECTIVES: Patients with rheumatoid arthritis (RA) have reduced serum low-density lipoprotein cholesterol (LDL-c), which increases following therapeutic IL-6 blockade. We aimed to define the metabolic pathways underlying these lipid changes. METHODS: In the KALIBRA study, lipoprotein kinetic studies were performed on 11 patients with severe active RA at baseline and following three intravenous infusions of the IL-6R blocker tocilizumab. The primary outcome measure was the fractional catabolic rate (FCR) of LDL...
November 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28192415/immune-regulation-by-glucocorticoids
#7
REVIEW
Derek W Cain, John A Cidlowski
Endogenous glucocorticoids are crucial to various physiological processes, including metabolism, development and inflammation. Since 1948, synthetic glucocorticoids have been used to treat various immune-related disorders. The mechanisms that underlie the immunosuppressive properties of these hormones have been intensely scrutinized, and it is widely appreciated that glucocorticoids have pleiotropic effects on the immune system. However, a clear picture of the cellular and molecular basis of glucocorticoid action has remained elusive...
April 2017: Nature Reviews. Immunology
https://www.readbyqxmd.com/read/28899798/is-acpa-positivity-the-main-driver-for-rheumatoid-arthritis-treatment-pros-and-cons
#8
REVIEW
Stefano Alivernini, Mauro Galeazzi, Hagit Peleg, Barbara Tolusso, Elisa Gremese, Gianfranco Ferraccioli, Yaakov Naparstek
Rheumatoid Arthritis (RA) is an autoimmune chronic disease that is characterized by the positivity of various antibodies, the most specific being autoantibodies against citrullinated antigens (ACPA). Despite ACPA are not arthritogenic by themselves, ACPA positive individuals have high risk of RA development and ACPA positivity is associated with severe erosive phenotype and higher mortality rate compared to seronegative RA. Moreover, ACPA status is associated with favorable response to biologics targeting pathways involving autoantibody producing cells as B lymphocytes...
November 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28870355/mechanical-ventilation-state-of-the-art
#9
REVIEW
Tài Pham, Laurent J Brochard, Arthur S Slutsky
Mechanical ventilation is the most used short-term life support technique worldwide and is applied daily for a diverse spectrum of indications, from scheduled surgical procedures to acute organ failure. This state-of-the-art review provides an update on the basic physiology of respiratory mechanics, the working principles, and the main ventilatory settings, as well as the potential complications of mechanical ventilation. Specific ventilatory approaches in particular situations such as acute respiratory distress syndrome and chronic obstructive pulmonary disease are detailed along with protective ventilation in patients with normal lungs...
September 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/28882850/two-new-drugs-for-rheumatoid-arthritis
#10
(no author information available yet)
Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease that causes inflammation and destruction of the joints.(1-3) It can also affect the eyes, the heart and the lungs and is associated with significant disability and increased mortality. RA is estimated to affect just under 1% of the population aged over 16 years, equating to more than 400,000 people in the UK.(4) ▼Baricitinib (Olumiant) and ▼tofacitinib (Xeljanz) were launched in the UK in April 2017 and represent a new therapeutic class of medicines known as targeted synthetic disease modifying antirheumatic drugs...
September 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27766916/a-real-world-risk-analysis-of-biological-treatment-adalimumab-and-etanercept-in-a-country-with-a-high-prevalence-of-tuberculosis-and-chronic-liver-disease-a-nationwide-population-based-study
#11
Y-M Chiu, C-H Tang, S-T Hung, Y-W Yang, C-H Fang, H-Y Lin
OBJECTIVES: Few studies on tumour necrosis factor (TNF) inhibitor-associated tuberculosis (TB) and hepatic events have been performed in regions where these risks are elevated. This study aimed to provide a direct comparison between adalimumab and etanercept in a high-risk population and to address the implications for physicians working with patients in such an environment. METHOD: Data collected from the National Health Insurance Research Database (NHIRD) in Taiwan between 2007 and 2011 were analysed retrospectively for incidences of eight adverse events associated with TNF-α inhibitors...
May 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/28854831/autoimmune-diseases-induced-by-biological-agents-a-review-of-12-731-cases-biogeas-registry
#12
REVIEW
Marta Pérez-De-Lis, Soledad Retamozo, Alejandra Flores-Chávez, Belchin Kostov, Roberto Perez-Alvarez, Pilar Brito-Zerón, Manuel Ramos-Casals
Biological drugs are therapies designed to target a specific molecule of the immune system that have been linked with the development of autoimmune diseases. Areas covered: The BIOGEAS Registry currently collects information about nearly 13,000 reported cases of autoimmune diseases developed in patients exposed to biologics, including more than 50 different systemic and organ-specific autoimmune disorders, of which psoriasis (n=6375), inflammatory bowel disease (n=845), demyelinating CNS disease (n=803), interstitial lung disease (n=519) and lupus (n=369) were the most frequently reported...
November 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28877868/impact-of-risk-factors-associated-with-cardiovascular-outcomes-in-patients-with-rheumatoid-arthritis
#13
Cynthia S Crowson, Silvia Rollefstad, Eirik Ikdahl, George D Kitas, Piet L C M van Riel, Sherine E Gabriel, Eric L Matteson, Tore K Kvien, Karen Douglas, Aamer Sandoo, Elke Arts, Solveig Wållberg-Jonsson, Lena Innala, George Karpouzas, Patrick H Dessein, Linda Tsang, Hani El-Gabalawy, Carol Hitchon, Virginia Pascual Ramos, Irazú Contreras Yáñez, Petros P Sfikakis, Evangelia Zampeli, Miguel A Gonzalez-Gay, Alfonso Corrales, Mart van de Laar, Harald E Vonkeman, Inger Meek, Anne Grete Semb
OBJECTIVES: Patients with rheumatoid arthritis (RA) have an excess risk of cardiovascular disease (CVD). We aimed to assess the impact of CVD risk factors, including potential sex differences, and RA-specific variables on CVD outcome in a large, international cohort of patients with RA. METHODS: In 13 rheumatology centres, data on CVD risk factors and RA characteristics were collected at baseline. CVD outcomes (myocardial infarction, angina, revascularisation, stroke, peripheral vascular disease and CVD death) were collected using standardised definitions...
September 6, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28865493/high-titers-of-both-rheumatoid-factor-and-anti-ccp-antibodies-at-baseline-in-patients-with-rheumatoid-arthritis-are-associated-with-increased-circulating-baseline-tnf-level-low-drug-levels-and-reduced-clinical-responses-a-post-hoc-analysis-of-the-rising-study
#14
Tsutomu Takeuchi, Nobuyuki Miyasaka, Takashi Inui, Toshiro Yano, Toru Yoshinari, Tohru Abe, Takao Koike
BACKGROUND: Although both rheumatoid factor (RF) and anticyclic citrullinated peptide antibodies (anti-CCP) are useful for diagnosing rheumatoid arthritis (RA), the impact of these autoantibodies on the efficacy of tumor necrosis factor (TNF) inhibitors has been controversial. The aim of this post hoc analysis of a randomized double-blind study (the RISING study) was to investigate the influences of RF and anti-CCP on the clinical response to infliximab in patients with RA. METHODS: Methotrexate-refractory patients with RA received 3 mg/kg of infliximab from weeks 0 to 6 and then 3, 6, or 10 mg/kg every 8 weeks from weeks 14 to 46...
September 2, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28845751/antiinflammatory-therapy-with-canakinumab-for-atherosclerotic-disease
#15
RANDOMIZED CONTROLLED TRIAL
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker, John J P Kastelein, Jan H Cornel, Prem Pais, Daniel Pella, Jacques Genest, Renata Cifkova, Alberto Lorenzatti, Tamas Forster, Zhanna Kobalava, Luminita Vida-Simiti, Marcus Flather, Hiroaki Shimokawa, Hisao Ogawa, Mikael Dellborg, Paulo R F Rossi, Roland P T Troquay, Peter Libby, Robert J Glynn
BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter...
September 21, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28867467/systematic-review-and-meta-analysis-of-the-efficacy-and-safety-of-leflunomide-and-methotrexate-in-the-treatment-of-rheumatoid-arthritis
#16
Roberto Alfaro-Lara, Hector Fabricio Espinosa-Ortega, César Alejandro Arce-Salinas
OBJECTIVE: To assess the efficacy and side effects of methotrexate and leflunomide in patients with rheumatoid arthritis (RA) as the first disease-modifying antirheumatic drug (DMARD). METHODS: We performed a systematic review and meta-analysis of clinical studies that included patients who took methotrexate, leflunomide, placebo or another DMARD for RA treatment. A systematic review yielded 1971 articles from databases; once completely reviewed, 73 trials that completed inclusion criteria were selected...
August 31, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28460018/evaluation-of-the-diagnostic-accuracy-of-hand-and-foot-mri-for-early-rheumatoid-arthritis
#17
Wouter P Nieuwenhuis, Hanna W van Steenbergen, Lukas Mangnus, Elize C Newsum, Johan L Bloem, Tom W J Huizinga, Saskia le Cessie, Monique Reijnierse, Annette H M van der Helm-van Mil
Objectives: To assess the diagnostic value of MRI for early RA. In some RA patients, a classifiable diagnosis cannot be made at first presentation; these patients present with unclassified arthritis (UA). The use of MRI for early diagnosis of RA is recommended, yet the evidence for its reliability is limited. Methods: MRI of hand and foot was performed in 589 early arthritis patients included in the Leiden Early Arthritis Clinic (229 presented with RA, 159 with other arthritides and 201 with UA)...
August 1, 2017: Rheumatology
https://www.readbyqxmd.com/read/28859326/similar-efficacy-and-safety-of-initial-cobra-light-and-cobra-therapy-in-rheumatoid-arthritis-4-year-results-from-the-cobra-light-trial
#18
RANDOMIZED CONTROLLED TRIAL
Nicole P C Konijn, Lilian H D van Tuyl, Maarten Boers, Debby den Uyl, Marieke M Ter Wee, Lindsey K M van der Wijden, Irene E M Bultink, Pit J S M Kerstens, Alexandre E Voskuyl, Dirkjan van Schaardenburg, Michael T Nurmohamed, Willem F Lems
Objective: To assess the efficacy and safety of initial COBRA-light vs COBRA therapy in RA patients after a 4-year follow-up period. Methods: In the COBRA-light trial, 162 consecutive patients with recent-onset RA were randomized to either COBRA-light (prednisolone and MTX) or COBRA therapy (prednisolone, MTX and SSZ) for 1 year. After 1 year, treatment was continued without protocol, and adjusted by the treating physician according to clinical judgement, preferably with a treat-to-target strategy...
September 1, 2017: Rheumatology
https://www.readbyqxmd.com/read/28866648/consensus-based-recommendations-for-the-use-of-biosimilars-to-treat-rheumatological-diseases
#19
Jonathan Kay, Monika M Schoels, Thomas Dörner, Paul Emery, Tore K Kvien, Josef S Smolen, Ferdinand C Breedveld
The study aimed to develop evidence-based recommendations regarding the evaluation and use of biosimilars to treat rheumatological diseases. The task force comprised an expert group of specialists in rheumatology, dermatology and gastroenterology, and pharmacologists, patients and a regulator from ten countries. Four key topics regarding biosimilars were identified through a process of discussion and consensus. Using a Delphi process, specific questions were then formulated to guide a systematic literature review...
September 2, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28861167/can-rheumatoid-arthritis-ever-cease-to-exist-a-review-of-various-therapeutic-modalities-to-maintain-drug-free-remission
#20
Di Liu, Na Yuan, Guimei Yu, Ge Song, Yan Chen
Therapies for rheumatoid arthritis (RA) were mostly aimed at reducing the pain, stiffness and further progression of joint destruction. However, with the advent of biologic agents that act against specific inflammatory cytokines contributing to RA pathogenesis (treat-to-target strategy), the degree of remission achieved has been remarkably impressive. In particular, inhibition of tumor necrosis factor α (TNFα), interleukins-1 and -6 and receptor-activator of nuclear kappa B ligand by neutralizing antibodies in early diagnosed RA patients has resulted in lowering of disease activity to levels that enable them to function as in the pre-disease stage...
2017: American Journal of Translational Research
label_collection
label_collection
7634
1
2
2017-09-08 12:22:42
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"